Skip to content
Erudio Health
menu
Clinical trial · no report yet · Phase 2

NCT06769126

Using Biomarker Tests to Select and Test New, Personalized Treatments for Extensive Stage Small Cell Lung Cancer, PRISM Study

  • NCT06769126 ↗
  • Recruiting
  • SWOG Cancer Research Network
  • 16 commentary sources found
  • Standard

We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.

Commentary we found

Podcasts, YouTube videos and X posts in our index that name this trial. A report screens them, searches for more and cites what clinicians said when it is built.

ChannelFound
YouTube7
X threads5
Podcasts3
X videos1

The trial

ClinicalTrials.gov
Official title
PRISM: PRecIsion in SCLC Via a Multicohort Study: Randomized Phase II Studies Evaluating Maintenance Durvalumab With or Without Biomarker-Directed Therapy for Extensive Stage Small Cell Lung Cancer (ES-SCLC)
Phase
Phase 2
Status
Recruiting
Conditions
Extensive Stage Lung Small Cell Carcinoma; Lung Small Cell Carcinoma, A Subtype; Lung Small Cell Carcinoma, I Subtype; Lung Small Cell Carcinoma, N Subtype; Lung Small Cell Carcinoma, P Subtype
Interventions
Biospecimen Collection; Ceralasertib; Computed Tomography; Durvalumab; Etoposide; Magnetic Resonance Imaging; Monalizumab; Platinum Compound; Positron Emission Tomography; Saruparib; Thoracic Radiation Therapy
Arms
  • Cohort A, Arm 1 (durvalumab) · Experimental
  • Cohort A, Arm 2 (durvalumab, saruparib) · Experimental
  • Cohort B, Arm 1 (durvalumab) · Experimental
  • Cohort B, Arm 2 (durvalumab, ceralasertib) · Experimental
  • Cohort C, Arm 1 (durvalumab) · Experimental
  • Cohort C, Arm 2 (durvalumab, monalizumab) · Experimental
Enrollment
900 (estimated)
Primary outcomes
  • Screen success rate (Screening)
  • Progression-free survival (PFS) (Cohort A)
  • PFS (Cohort B)
  • PFS (Cohort C)
Sponsor
SWOG Cancer Research Network with National Cancer Institute (NCI)
Start
Nov 6, 2025
Primary completion
Dec 31, 2028 (estimated)
Results posted
No
Registry record
NCT06769126 · updated Mar 30, 2026